Drugs / 18F-JNJ-64326067
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03581916 | Jul → Nov 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-JNJ-64326067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03581916 ↗ |
| Route | Intravenous | “administered intravenously” NCT03581916 ↗ |